320 results on '"Valim, Valéria"'
Search Results
52. Perfil do uso de drogas modificadoras de doença no Registro Brasileiro de Espondiloartrites
53. Transcultural adaptation of the “EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)” into Brazilian Portuguese
54. Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis
55. Artrite enteropática no Brasil: dados do registro brasileiro de espondiloartrites
56. Adaptação transcultural do “EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)” para a língua portuguesa
57. Current Approach to Dry Eye Disease
58. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis
59. Primary Sjögren's syndrome prevalence in a major metropolitan area in Brazil
60. Prevalência da síndrome de Sjögren primária em importante área metropolitana no Brasil
61. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL
62. REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
63. EVENTOS ADVERSOS ÀS VACINAS CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES DA SAÚDE
64. REATIVIDADE VACINAL E DURAÇÃO DE RESPOSTA IMUNE DA CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES
65. EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)
66. CORRELAÇÃO CLÍNICA COM REATIVIDADE IMUNE APÓS INFECÇÃO LEVE A MODERADA POR COVID-19 EM UMA COORTE DE TRABALHADORES DA SAÚDE
67. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)
68. Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
69. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium
70. Clinical risk factors for predicting anti-Sars-Cov-2 antibody immunoreactivity duration after mild COVID-19 infection.
71. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions
72. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions
73. Prevalência de lesão periapical radiolúcida nos pacientes com síndrome de Sjögren primária
74. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)
75. EDUCATIONAL PROGRAM ASSOCIATED WITH THERAPEUTIC INTERVENTIONS SIGNIFICANTLY REDUCE PAIN AND FUNCTIONAL DISABILITY IN PATIENTS WITH CHRONIC SPINE PAIN
76. HIGH PREVALENCE OF CANCER AMONG PRIMARY SJÖGREN’S SYNDROME: DATA FROM BRAZILIAN SJÖGREN’S SYNDROME REGISTRY (RE-BRASS)
77. Hydroxychloroquine Impairs Primary Humoral Response after Yellow Fever Vaccination in Primary Sjögren’s Syndrome
78. PRIMARY SJÖGREN'S SYNDROME PATIENTS WITH BETTER LEVELS OF PHYSICAL ACTIVITY PRESENT LESS FATIGUE AND BETTER QUALITY OF LIFE
79. A RARE OVERLAP OF JUVENILE IDIOPATHIC ARTHRITIS AND SARCOIDOSIS: CASE REPORT
80. BIOLOGICAL THERAPY EVEN AFTER WASHED OUT DECREASES IMMUNE RESPONSE OF YELLOW FEVER PRIMARY VACCINATION IN SPONDYLOARTHRITIS
81. EPIDEMIOLOGICAL, CLINICAL AND LABORATORY ANALYSIS OF PATIENTS WITH TAKAYASU ARTERITIS AT HOSPITAL UNIVERSITÁRIO CASSIANO ANTÔNIO DE MORAES
82. EVALUATION OF THE EFFECTIVENESS AND SAFETY OF REMSIMA (INFLIXIMAB BIOSSIMILAR) IN COMPARISON WITH THE REMICADE, IN PATIENTS WITH TAKAYASU'S ARTERITIS
83. HIGH BASDAI SCORES DID NOT REDUCE IMMUNE RESPONSE TO PLANNED YELLOW FEVER PRIMARY VACCINATION IN SPONDYLOARTHRITIS
84. PERSISTENT LYMPHADENOPATHY IN LUPUS PATIENT ASSOCIATED WITH CASTLEMAN'S DISEASE: A CASE REPORT
85. DIAGNOSIS OF DERMATOMYOSITIS TWO MONTHS AFTER COVID-19 INFECTION
86. AUTOIMMUNE INFLAMMATORY MYOPATHY AFTER CHIKUNGUNYA INFECTION
87. OBSTRUCTIVE HYDROCEPHALUS DUE TO AQUEDUCTAL STENOSIS IN AN ELDERLY MAN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CASE REPORT
88. BRAZILIAN VERSION OF THE "PRIMARY SJÖGREN SYNDROME - QUALITY OF LIFE QUESTIONNAIRE (PSS-QOL)
89. Purple after Adalimumab: a case report
90. LEUKOCYTOCLASTIC VASCULITIS AND THROMBOSIS IN PRIMARY SJÖGREN SYNDROME AFTER COVID-19: A CASE REPORT
91. COVID-19 INFECTION IN A PATIENT WITH LUPUS PROGRESSING TO VERTEBRAL ARTERY DISSECTION AND ISCHEMIC STROKE
92. MULTIBACILAR LEPROSY MIMICKING SYSTEMIC LUPUS ERYTHEMATOSUS
93. LUPUS LIKE SYNDROME FOLLOWING PARVOVIRUS B19 INFECTION
94. Serum Biomarker Profile Orchestrating the Seroconversion Status of Patients With Autoimmune Diseases Upon Planned Primary 17DD Yellow Fever Vaccination
95. Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
96. Juvenile Sjögren's Syndrome: Clinical Characteristics With Focus on Salivary Gland Ultrasonography
97. Chronic Inflammatory Arthropathy Preceding Acute Systemic Manifestations of Sarcoidosis: A Possible Overlap of Idiopathic Juvenile Arthritis and Sarcoidosis
98. Yellow Fever Virus Genotyping Tool and Investigation of Suspected Adverse Events Following Yellow Fever Vaccination
99. A Randomized Controlled Trial of Deep Water Running: Clinical Effectiveness of Aquatic Exercise to Treat Fibromyalgia
100. Health-related quality of life and costs in Sjögren's syndrome.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.